A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight

Running, not enrolling · Phase 3 · Has a placebo group

Conditions studied: Obesity, Overweight

In brief

The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction. Participation in the study will last about 65 weeks and may include about 18 visits.

Key facts

Study ID

NCT07232719

Run by

Eli Lilly and Company

People needed

250

Starts

2025-11-17

Expected to finish

2027-07-01

Last updated by the study team

2026-04-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have a body mass index (BMI) of:
• ≥30 kilogram per square meter (kg/m2) OR
• ≥27 kg/m2 with at least one of the following weight-related conditions: high blood pressure, abnormal levels of lipid, obstructive sleep apnea, heart disease
• Have at least one unsuccessful attempt to lose weight by dieting

You may not qualify if…

• Have a self-reported change in body weight >5 kg (11 pounds) within 90 days before screening
• Have a prior or planned surgical treatment for obesity
• Have type 1 diabetes or type 2 diabetes
• Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
• Have had within the past 90 days before screening
• acute myocardial infarction
• cerebrovascular accident (stroke)
• hospitalization for unstable angina, or
• hospitalization due to congestive heart failure
• Have New York Heart Association Functional Classification Class IV congestive heart failure
• Have a history of chronic or acute pancreatitis
• Have taken weight loss drugs, including over-the counter medications within 90 days prior to screening

Where it is running

• Artemis Institute for Clinical Research — Riverside, California, United States
• JEM Research Institute — Atlantis, Florida, United States
• Headlands Research Orlando — Orlando, Florida, United States
• Care Access - Tamarac — Tamarac, Florida, United States
• Care Access - Arlington Heights — Arlington Heights, Illinois, United States
• L-MARC Research Center — Louisville, Kentucky, United States
• IMA Clinical Research Monroe - Armand — Monroe, Louisiana, United States
• Pharmasite Research, Inc. — Baltimore, Maryland, United States
• Clinical Research Professionals — Chesterfield, Missouri, United States
• Clinvest Headlands Llc — Springfield, Missouri, United States
• IMA Clinical Research Warren — Warren Township, New Jersey, United States
• IMA Clinical Research Manhattan — New York, New York, United States
• Trial Management Associates - Wilmington - Floral Parkway — Wilmington, North Carolina, United States
• Cedar Health Research — Dallas, Texas, United States
• Headlands Research-El Paso — El Paso, Texas, United States
• Cedar Health Research - Euless — Euless, Texas, United States
• Cedar Health Research - Fort Worth — Fort Worth, Texas, United States
• Care Access - Houston — Houston, Texas, United States
• IMA Clinical Research San Antonio — San Antonio, Texas, United States
• FutureMeds - Birmingham — Birmingham, United Kingdom
• Layton Medical Centre — Blackpool, United Kingdom
• Bradford on Avon Health Centre — Bradford-on-Avon, United Kingdom
• FutureMeds - Liverpool — Bromborough, United Kingdom
• Cheadle Community Hospital — Cheadle, United Kingdom
• HMC Health Group - Meadows Centre for Health — Hounslow, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.